Citations

Clear

64 citation(s) found for "Snow, C".

Molecular analysis of NUT‐positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions
Snow, Justin T., Georgantzoglou, Natalia , Green, Donald C., Parra, Ourania , LeBlanc, Robert E. , Yan, Shaofeng , Sriharan, Aravindhan, Momtahen, Shabnam , Winnick, Kimberley N., Dimonitsas, Emmanouil , Stavrianos, Spiros, Lakiotaki, Eleftheria , Revelos, Kyriakos , Guo, Ruifeng , Linos, Konstantinos , Linos, Konstantinos , Guo, Ruifeng , Stavrianos, S. , Korkolopoulou, Penelope A.

Mayo Clinic

Journal of Cutaneous Pathology | June 4, 2022 | Volume: 49 | Issue: 10 | Pages: 850-858

10.1111/cup.14265 | PMID 35665951 Get It

AbstractBackgroundPoromas, and their malignant counterparts, porocarcinomas, harbor recurrent translocations involving YAP1‐MAML2, YAP1‐NUTM1, and infrequently WWTR1‐NUTM1; YAP1‐NUTM1 being the most common in porocarcinomas. NUT immunohistochemistry (IHC) can be used to identify NUTM1‐translocated tumors. This study sought to investigate potential novel NUTM1‐fusion partners among NUT IHC‐positive poromas and porocarcinomas.MethodsThirteen NUT IHC‐positive poroid tumors (four poromas and nine porocarcinomas) were identified within a multi‐institutional international cohort. Next‐generation sequencing (NGS) assessed for NUTM1 fusion partners.ResultsNGS detected a NUTM1 fusion in 12 of 13 cases: YAP1‐NUTM1 (11/12 cases) and WWTR1‐NUTM1 (1/12 cases). Two of the cases (2/12) with NUTM1 fusion were not called by the NGS algorithm but had at least one read‐spanning YAP1‐NUTM1 break point upon manual review. A NUTM1 fusion was not identified in one case; however, the sample had low RNA quality. The following fusion events were identified: YAP1 exon 4::NUTM1 exon 3 in six cases, YAP1 exon 6::NUTM1 exon 2 in one case, YAP1 exon 3::NUTM1 exon 3 in three cases, WWTR1 exon 3::NUTM1 exon 3 in one case, and YAP1 exon 8::NUTM1 exon 3 fusion in one case.ConclusionWhile no novel NUTM1 fusion partners were identified within our cohort, 12 of 13 cases had discoverable NUTM1 fusions; YAP1‐NUTM1 fusion was detected in 11 cases (92%) and WWTR1‐NUTM1 in 1 case (8%). These data corroborate findings from other recent investigations and further substantiate the utility of NUT IHC in diagnosing a subset of poroid neoplasms. In addition, two of our cases harbored fusions of YAP1 exon 6 to NUTM1 exon 3 and YAP1 exon 8 to NUTM1 exon 2, which have not been reported before in poroid neoplasms and indicate novel break points of YAP1.
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
Waks, Adrienne G. , Kim, Dewey, Jain, Esha , Snow, Craig, Kirkner, Gregory J., Rosenberg, Shoshana M., Oh, Coyin, Poorvu, Philip D., Ruddy, Kathryn J. , Tamimi, Rulla M. , Peppercorn, Jeffrey, Schapira, Lidia , Come, Steven E., Brachtel, Elena F. , Warner, Ellen, Collins, Laura C., Partridge, Ann H., Wagle, Nikhil, Borges, Virginia F , Brachtel, Elena F , Tamimi, Rulla M , Waks, Adrienne G , Kim, Dewey, Jain, Esha , Snow, Craig, Kirkner, Gregory J., Rosenberg, Shoshana M., Oh, Coyin, Poorvu, Philip D., Ruddy, Kathryn J , Peppercorn, Jeffrey, Schapira, Lidia , Come, Steven E., Warner, Ellen, Collins, Laura C., Partridge, Ann H., Wagle, Nikhil

Mayo Clinic

Clinical Cancer Research | January 31, 2022 | Volume: 28 | Issue: 11 | Pages: 2339-2348

10.1158/1078-0432.ccr-21-2572 | PMID 35101884 Get It

Abstract Purpose: Young age at breast cancer diagnosis correlates with unfavorable clinicopathologic features and worse outcomes compared with older women. Understanding biological differences between breast tumors in young versus older women may lead to better therapeutic approaches for younger patients. Experimental Design: We identified 100 patients ≤35 years old at nonmetastatic breast cancer diagnosis who participated in the prospective Young Women's Breast Cancer Study cohort. Tumors were assigned a surrogate intrinsic subtype based on receptor status and grade. Whole-exome sequencing of tumor and germline samples was performed. Genomic alterations were compared with older women (≥45 years old) in The Cancer Genome Atlas, according to intrinsic subtype. Results: Ninety-three tumors from 92 patients were successfully sequenced. Median age was 32.5 years; 52.7% of tumors were hormone receptor-positive/HER2-negative, 28.0% HER2-positive, and 16.1% triple-negative. Comparison of young to older women (median age 61 years) with luminal A tumors (N = 28 young women) revealed three significant differences: PIK3CA alterations were more common in older patients, whereas GATA3 and ARID1A alterations were more common in young patients. No significant genomic differences were found comparing age groups in other intrinsic subtypes. Twenty-two patients (23.9%) in the Young Women's Study cohort carried a pathogenic germline variant, most commonly (13 patients, 14.1%) in BRCA1/2. Conclusions: Somatic alterations in three genes (PIK3CA, GATA3, and ARID1A) occur at different frequencies in young versus older women with luminal A breast cancer. Additional investigation of these genes and associated pathways could delineate biological susceptibilities and improve treatment options for young patients with breast cancer. See related commentary by Yehia and Eng, p. 2209
Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19
Gillet, A.S. , Zu, Yuanhao, Brown, Margo, Pham, Thaidan , Yoshida, Yilin , Douglas, Ivor S. , Moore, Mathew, Tea, Kevin, Wetherbie, Andrew, Stevens, Rachael, Lefante, John J., Shaffer, Jeffrey G. , Armaignac, Donna Lee , Belden, Katherine A. , Kaufman, Margit, Heavner, Smith F. , Danesh, Valerie , Hill, Catherine A. St., Boman, Karen , Bansal, Vikas , Kumar, Vishakha K. , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Mesland, Jean-Baptiste , Henin, Pierre , Petre, Hélène, Buelens, Isabelle, Gérard, A , Granado, Rolando Claure-Del, Vega-Terraza, Esdenka, Iturricha-Cáceres, Maria F., Garza, Rubén , Chan, Victoria , Gavidia, Oscar Y., Pachon, Felipe, Tawheed, Ahmed , Pineda, Estela , Guillen, Gabina María Reyes, Soto, Helin Archaga, Lizardo, Ana Karen Vallecillo, Segu, Smitha, Chakraborty, T., Joyce, Epcebha, Kasumalla, Phani Sreeharsha, Vadgaonkar, Girish, Ediga, Rekha, Basety, Shilpa, Dammareddy, Shwetha, Raju, Umamaheswara, Manduva, Janaki, Kolakani, Naresh, Sripathi, Shreeja , Chaitanya, Sheetal, Parameswaran, Sreejith , Parthiban, Magesh, Menu, P., Daga, Mardul Kumar, Agarwal, Munisha , Rohtagi, Ishan, Papani, Sridhar, Kamuram, Mahesh, Agrawal, Kamlesh Kumar , Baghel, Vijendra, Patel, K, Mohan, Surapaneni Krishna, Jyothisree, Ekambaram, Dalili, Nooshin , Nafa, Mohsen, Matsuda, Wataru , Suzuki, Reina , Horikita, Sho, Kodate, Akira, Takahashi, Yuki , Moriki, Koyo, Iwasaki, Yudai , Rodríguez‐Gutiérrez, René , Gonzale, Jose Gerardo, Salcido‐Montenegro, Alejandro , Hassan-Hanga, Fatimah , Gezawa, Abubakar Shehu, Kabir, Halima , Amole, Taiwo Gboluwaga , Haliru, Dalha Gwarzo, Ibrahim, Abdullahi S., Asghar, Muhammad Sohaib , Syed, Mashaal , Naqvi, Syed Anosh Ali, Заболотских, И. Б. , Alamoudi, Razan K., Alsharif, Hassan, Almazwaghi, Sarah A., Elsakran, Mohammed S., Aid, M., Darwich, Mouaz A., Hagag, Omnia M., Ali, Salah A., Rocacorba, Alona, Supeña, Kathrine, Juane, Efren Ray, Medina, Jenalyn, Baduria, Jowany, Amer, Marwa , Dahhan, Talal, Kseibi, Eiad, Butt, Abid Shahzad, Khurshid, Syed Moazzum, Rabee, Muath, Abujazar, Mohammed, Alghunaim, Razan K, Abualkhair, Maal, AlFirm, Abeer Turki, Alarifi, Mohammed I, Macarambon, Jara Mia, Bukhari, Ahmad Abdullah, Albahrani, Hussian A, Aldossary, Kaltham M., Zoran, Marija Zdravkovic, Popadic, Viseslaz, Bojicic, Jovana, Predrag, Stevanović, Stojakov, Dejan , Ignjatovic, Duska K., Bojicic, Suzana C, Bobos, Mariana M, Nenadić, Irina , Zaric, Milica S., Djuric, Marko , Djukic, Vladimir R., Teruel, Santiago, Martin, Belen C., Bilgin, Huseyin, Dodd, Kenneth W. , Goodmanson, Nicholas, Hesse, Kathleen, Bird, P. H., Weinert, Chauncey, Schoenrade, Nathan, Altaher, Abdulrahman, Mayar, Esmael, Aronson, Matthew, Cooper, Tyler, Logan, Monica, Miner, Brianna, Papo, Gisele, Siegal, Eric M., Runningen, Phyllis, Patel, Love , Melamed, Roman , Tierney, David M. , Raj, Vino S., Mazumder, Narayana, Hill, Catherine St., Kirkland, Lisa L., Schmitz, Nova J., Sigman, Alena, Hall, Joan, Raval, Abhijit, Franks, Andrea S. , Jarvis, Jennifer M., Kharbanda, Anmol, Jhajhria, Sunil, Fyffe, Zachary, Capizzi, Stephen A., Alicie, Bethany, Green, Martha, Corckarell, Lori, Drennan, A. M., Dubuque, Kathleen, Fambrough, Tonya, Gasaway, Nikole, Krantz, Briana, Nebi, Peiman, Orga, Jan, Serfass, Margaret, Simion, Alina, Warren, Kimberly R., Wheeler, Cassie, Woolman, C. J., Christie, Amy B. , Adiga, Rajani, Moyer, A, Verghese, George M., Forehand, Chirsty C, Sabov, Moldovan, Zaidi, Fatema, Tissavirasingham, Fiona, Malipeddi, Dhatri , Campbell, Beth Salvagio , Wilson, Cathleen, Rivers, Patrick , Brinks, Jonathan, Mongoh, Mokenge Ndiva, Gilson, Boris, Armaignac, Donaa Lee, Parris, Don, Zuniga, Maria Pilar, Vargas, Ilea, Boronat, Viviana, Hutton, Anneka, Kaur, Navneet , Neupane, Prashank, Sadule-Rios, Nohemi, Rojas, Lourdes M. , Neupane, Aashish, Rivera, Priscilla, Carlos, Carlos Valle, Amin, Mahesh, Schelle, Mary E, Steadham, Amanda, McBride, Cameron , Abraham, Jocelyn, Richards, Katherine , Collins, Keegan, Antony, Preethi, Dubrocq, Gueorgui , Davis, Amber, Hammers, Marissa J, McGahey, Ill M, Farris, Amanda C., Priest, Elisa L. , Korsmo, Robyn, Fares, Lorie, Skiles, Kathy, Shor, Susan M, Burns, Kenya, Flores, Melody, Newman, Lindsay, Wilk, Debora A., Ettlinger, Jason, Bomar, Jaccallene, Darji, Himani, Arroliga, Alejandro C. , Dowell, Corrie A., Gonzales, Gabriela “ Hope”, Garcia, Michael A. , Colona, Mia R., Kibbelaar, Zoé A. , Leong, Michael S. , Wallman, Daniel , Soni, Kanupriya , Maccarone, Jennifer , Gilman, Joshua, Devis, Ycar, Chung, Joseph, Paracha, Munizay , Lumelsky, David , DiLorenzo, Madeline A. , Abdurrahman, Najla, Johnson, Shelsey W. , Hersh, Maj Andrew M., Wachs, Stephanie, Swigger, Brittany S., Sattler, L, Moulton, Michael N., Zammit, Kimberly, Loeffler, William, Tirupathi, Raghavendra , Tang, Alymer, Safi, Arshad M., Green, Cindy, Newell, J.D., Ramani, Naga, Ganti, Bhavani Harika, Ihle, R , Davis, Elaine , Martin, Shelda A, Sayed, Imran A., Strom, Larisa, Lee, Giyoung , Burnett, Ryan H., Sydney, Guy I. , Traynor, Danielle M., White, Joshua, Khan, Aftab, Dhahwal, Rahul, Ahmed, Farzin, Deonarine, Chrispoter, Jones, Ashley, Shaikh, Mohammad Ali, Preston, David A. , Chin, Jeanette, Duggal, Abhijit, Rajendram, Prabalini , Mehkri, Omar , Biehl, Michelle, Houltham, Stuart, Kind, Alexander, Ashok, Kiran, Poynter, Bryan, Beukemann, Mary, Rice, Richard, Gole, Susan, Shaner, Valerie , Conjeevaram, Adarsh, Ferrari, Michlelle, Alappan, Narendrakumar, Minear, Steven , Hernández-Montfort, Jaime , Nasim, Syed Sohaib, Sunderkrishnan, Ravi, Sahoo, Debasis , Milligan, Patrick S., Koglin, Joy M., Gibson, Regina, Johnson, Lana, Preston, Felicia, Scott, Crimson, Nungester, Bethany, Byrne, Dana , Grant, Katie, Doktar, Katherine L, Porto, Maura C, Kaplan, Olgo, Schonewald, Brian, Woodford, Ashley L., Tsai, Alan , Reid, Savina, Bhowmick, Kuntal, Daneshpooy, Saba , Mowdawalla, Cyrus , Dave, Trishna Akshay, Crudeli, Wilhemina Kennedy Connor, Ferry, Chirstopher, Nguyen, Long , Modi, Sneha, Padala, Niharika, Patel, Pavan Jitendra, Lin, Belle, Qiuyun, Jamie, Liu, Fan Mandi, Kota, Rasagna, Banerjee, Annesha , Daugherty, Steven K., Atkinson, Sam, Shrimpton, Kelly, Ontai, Sidney , Contreras, Brian, Obinwanko, Uzoma, Amamasi, Nneka, Sharafi, Amir, Lee, Sarah , Esber, Zahia , Jinjvadia, Chetna, Krishnamoorthy, Vijay , Kraft, Bryan , Pulsipher, Aaron, Friedman, Eugene, Mehta, Sachin , Kaufman, Margit, Lobel, G, Gandhi, Nisha, AbdelAty, Amr M. , Shaji, Elizabeth, Lim, Kiana, Marte, Juan M., Sosa, Dani Ashley, Benjenk, Ivy , Prasanna, Nivedita, Perkins, Nicholas , Roth, Prera J, Litwin, Alain H. , Pariyadath, Ananda, Moschella, Phillip , Llano, Trayson, Waller, Christine, Kallies, Kara J. , Thorsen, Jonean , Fitzsimmons, Alec , Olsen, H. L., Smalls, Normal, Davis, S., Jovic, Valentina, Masuda, M, Hayes, Amanda, Nault, Katharine, Snow, William G., Liptak, Riley, Durant, Hannah, Pendleton, Valerie, Nanavati, Alay, Mrozowsk, Risa, Doubleday, Erica, Liu, Yuk Min, Zavala, Sarah , Shim, Esther, Reilkoff, Ronald A., Eichen, Sarah, Goertzen, Lexie, Rajala, Scott, Feussom, Ghislaine, Junia, Christine, Lichtenberg, Robert, Sidhu, Hasrat, Espinoza, Diana , Rodrigues, Shelden , Zabala, Marai Jose, Susheela, Ammu , Hatharaliyadda, Buddhi, Rameshkumar, Naveen, Kasireddy, Amulya, Beltran, Lisseth, Chaugule, Akshata, Patil, Namrata, Patil, Ruhi, Cartin‐Ceba, Rodrigo , Sen, Ayan , Talaei, Fahimeh , Domecq, Juan Pablo , Gajic, Ognjen, Sharma, Mayank , Qamar, Shahraz , Morales, Diana J. Valencia , Nou, Abigail T. La, Bogojevic, Marija , Sanghavi, Devang , Franco, Pablo Morno, Ganaphadithan, Karthik, Saunders, Hollie , Fleissner, Zachary, Mateus, Alejandra Yu Lee, Kaur, Nirmaljot , Giri, Abhisekh, Hasan, Mohammed Mustafa, Donepudi, Ashrita , Khan, Syed Anjum , Jain, Nitesh , Koritala, Thoyaja , Nanchal, Rahul , Peterson, Jennifer , Yamanaka, Travis, Barreras, Nicholas A., Markos, Michael, Fareeduddin, Anita, Mehta, Rohan, Venkata, Chakradhar , Engemann, Miriam, Mantese, Annamarie, Tarabichi, Yasir , Wang, Christine, Kotekal, Dhatri, Bierwirth, Adriana C. Briceno, Orellana, Gabriela, Catalasan, Gerardo , Ahmed, Shohana, Salinas, Ivania, Nogal, Genesis Del, Tejada, Ángel Morales-Martínez de, Chen, Jen‐Ting , Hope, Aluko A. , Tsagaris, Zoe, Ruen, Elise, Hambardzumyan, Aram, Siddiqi, Nasar A, Jurado, Lesly, Tincher, Lindsey, Brown, Carolyn , Aulakh, Bhagat , Bandy, Jennifer A., Kreps, Lisa M., Bollinger, Dwan R, Stienecker, Roger Scott , Melendez, Andre G, Brunner, Tressa A., Budzon, Sue M., Heffernan, J., Souder, Janelle M., Miller, Tracy L., Maisonneuve, A., Redfern, Roberta E. , Shoemaker, Jessica, Micham, Jennifer, Kenney, Lynn, Naimy, Gabriela, Pulver, Kerry P J, Yehle, Jennifer, Weeks, Alicia, Inman, T., Delmonaco, Brain L, Franklin, Anthony , Heath, Mitchell, Vilella, Antonia L. , Kutner, Sara B., Clark, Kacie , Anderson, Harry L, Rajkumar, Dixy, Abunayla, Ali, Heiter, Jerrilyn, Zaren, Howard A. , Smith, Stephanie J., Lewis, Grant C., Seames, Lauren, Farlow, Cheryl, Miller, Judy, Broadstreet, Gloria, Martinez, Anthony , Allison, Micheal, Mittal, Aniket, Ruíz, Rafael Azuar , Skaanland, Aleta, Patel, Umang, Hodge, Jordesha, Patel, Krunal Kumar, Dalal, Shivani , Kavani, Himanshu , Joseph, Sam W. , Bernstein, Michael, Goff, Ian K., Naftilan, Matthew, Mathew, Amal , Williams, Debora, Murdock, Sue, Ducey, Maryanne, Nelson, Kerianne, Mitchel, James, Cox, Sylvan, Amzuta, Ioana, Shah, Amish , Modi, Ritu, Al-Khalisy, Hassan, Masuta, Pradeep, Schafer, Melissa , Wratney, Angela, Carter, K., Olmos, M. A. Martinez, Parker, Brittany M, Quintanilla, Julio, Craig, Tara A, Clough, B., Jameson, J, Jones, Tacy L, Ayers, Shonda C., Harrell, Amy B., Brown, Brent R., Darby, Caleb, Page, Kristy, Brown, Amanda, McAbee, Jessie, Baram, Michael , Weber, Devin , DePaola, Rosalie, Xia, Yuwei , Carter, Hudson, Tolley, A. E., Ferranti, Mary, Steele, Mark P., Kemble, Laurie, Sethi, Joshua, Han, Chung Cheng, Pagliaro, Jaclyn , Husian, Abdurrahman, Zawaydeh, Qais , Sines, B. , Markotić, Dragana, Bošnjak, Ivana, Nicholson, Susannah E. , Jonas, Rachelle B., Dement, AnnaRose E, Tang, William , DeRose, Mark, Villarreal, Robert E, Dy, Rajany , Lardino, Alfredo, Sharma, Jill H., Czieki, Richard, Christopher, Julia, Lacey, Ryan, Mashina, Marwan , Patel, Kushal, Gomaa, Dina , Goodman, Micahel, Spuzzillo, Anthony , Shinn, John O., Baslanti, Tezcan Ozrazgat, Omalay, George, Hashemighouchani, Haleh , Cupka, Julie S , Galet, Colette , Hubbard, Janice, Nazir, Usman, Rampon, Garrett , Riggle, Jake, Dismag, Nathan, Lenhardt, Rainer, Cavallazzi, Rodrigo , Jerde, Ann, Black, Alexa, Polidori, A., Griffey, Haily, Winkler, J., Brenzel, Thomas, Alvarez, Rodger A, Alarocon-Calderon, Amarilys, Sosa, Marie Anne , Mahabir, Sunita, Patel, Mausam , Parker, Pauline, Admon, Andre, Hanna, Sinan, Pliakas, Maria , Wolski, Ann, Cirino, Jennifer, Geiger, Grant , Njai, Abdoulie , Saad, Baraa M., Chuan, Byron, Rawal, Sagar L, Piracha, Manal, Levin, Nicholas M. , Suslavich, Kayte , Tsolinas, Rachel , Fica, Zachary , Skidmore, Chloe R., Stapleton, Renee D., Dixon, Anne E. , Johnson, Olivia, Ardren, Sara S., Burns, Stephanie, Raymond, Anna, Gonyaw, Erika, Hodgdon, Kevin , Houseger, Chole, Lin, Benjamin R. , McQuesten, Karen, Grimm, Heidi Pecott-, Sweet, Julie, Ventrone, Sebastian, Khandelwal, Nita , Lovelace-Macon, Lara, Garimella, Navya, Dow, Denisse Bazan, Rahman, Rania Abdul, Mulrow, Mary, Wilfong, Erin M. , Vela, Kelsi, Harris, Lynne, Cusson, Bruce, Fowler, Jacob , VanEenenaam, David P., Mckinney, Glen , Udoh, Imoh, Johnson, Kathleen N. , Michelson, Andrew P. , Haulf, Sara S, Lynch, Lauren, Steinbery, Aaron, Braus, Nicholas, Pattan, Vishwanath , Papke, J, Jimada, Ismail, Mhid, Nida, Chakola, Samuel, Sheth, Kevin N., Ammar, Abdalla , Lopez, Victor Torres , Khosla, Akhil , Gautam, Samir C. , Lee‐Mateus, Alejandra Yu , Bansal, Vikas , Yu Lee-Mateus, Alejandra , Kaur, Nirmaljot , Asghar, Muhammad S , Redfern, Roberta E , Denson, Joshua L. , Mauvais‐Jarvis, Franck , Cheruku, Sreekanth , Deo, Neha , Walkey, Allan J. , Kashyap, Rahul , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Clevenbergh, Philippe Albert , Granado, Rolando Claure‐Del , Mercado, Jose A, Garza, Ruben, Chu, Eric, Chan, Victoria, El‐Kassas, Mohamed , Chakraborty, Tuhin, Cherian, Anusha , Menu, Priya A, Sanui, Masamitsu , Itagaki, Yuki , Shiga, Takuya , Camacho-Ortíz, Adrián , Galadanci, Hadiza , Syed, Mashaal, Musaeva, Tatiana Sergeevna , Bawazeer, Mohammed Abdullah , Alghunaim, Razan K, Almazyad, Mohammed , Asfina, Kazi Nur , Klašnja, Slobodan , Kovačević, Bojan , Teruel, Santiago Y, Sili, Uluhan , Ay, Pınar , Bird, Paige, Schoenrade, Nathan, Hall, Joan, Franks, Andrea, Drennan, Amelia, Warren, Kimberly, Ashley, Dennis W. , Sikora, Andrea , Bruning, Rebecca, Jones, Timothy W, Mosier, Jarrod , Lutrick, Karen , Vincent, Gregory, Howard, Christopher M. , Garner, Orlando , Mathew, Sindhu, Dubrocq, Gueorgui , Waikar, Sushrut S. , Leong, Michael, McGrath, Patrick J, Chilbert, Maya R. , Green, Cindy, Ihle, Rayan E, Martin, Shelda A., Gist, Katja M. , Chiotos, Kathleen , Blatz, Allison M. , Surani, Salim , White, Joshua, Khan, Aftab, Preston, David, Vachharajani, Vidula , Dugar, Siddharth , Sacha, Gretchen , Kind, Alexander, Gole, Susan, Gupta, Sandeep , Schorr, Christa , Siegler, James E. , Bartz, Raquel R. , Mehta, Sachin, Kaufman, Margit, Abdelaty, Amr, Yamane, David , Pariyadath, Anand, Olsen, Haley, Smith, Michael A. , Snow, William, Heneghan, Julia A. , Tang, Ben, Goyes, Daniela , Maldonado, Génessis , Khan, Hassan, Gajic, Ognjen , Tekin, Aysun , Lal, Amos , O’Horo, John C. , Singh, Romil , Nou, Abigail La, Zec, Simon , Guru, Pramod , Garcia, Juan, Yarrarapu, Siva Naga S. , Bergl, Paul A. , Peterson, Jennifer L, Perzynski, Adam T. , Wang, Christine, Matute, Carlos , Hamdan, Ahmad, Tejada, Angel, Tripathi, Sandeep , Inman, Terra, Moore, Danielle, Anderson, Harry L, Miller, Judy, Ruiz, Rafael, Ross, Robert, Joseph, Sam, Block, Jason, O’Brien, Connor , Carter, Kristina L, Olmos, Michael, Gupta, Neha , Darby, Caleb, Tolley, Aaron, Malhotra, Atul , Bice, Thomas J. , Bosnjak, Ivana, Vail, Emily A. , Tang, William, Villarreal, Roberto E., Patel, Kushal, Wakefield, Devin, Bihorac, Azra , Ruppert, Matthew M. , McGonagill, Patrick W. , Wang, David , Allan, Lauren , Badheka, Aditya V. , Chegondi, Madhuradhar , Akça, Ozan , Polidori, Allison, Winkler, Justin, Chanderraj, Rishi , Dandachi, Dima , Regunath, Hariharan , Camazine, Maraya , Saad, Baraa, Shah, Faraaz A , Tonna, Joseph E. , Lin, Benjamin, Pecott-Grimm, Heidi, West, T. Eoin , Caldwell, Ellen , Akhter, Murtaza , Khanna, Ashish , Lyons, Patrick G. , Lynch, Lauren M, Nguyen, Nguyet Minh , Papke, Jessica, Ammar, Mahmoud A , Dela Cruz, Charles S

Mayo Clinic

JAMA Network Open | December 22, 2021 | Volume: 4 | Issue: 12 | Pages: e2140568

10.1001/jamanetworkopen.2021.40568 | PMID 34935924 Get It

Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors.
Sella, Tal , Fell, Geoffrey, Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Fell, Geoffrey G. , Miller, Peter G. , Gibson, Christopher James , Snow, Craig , Stover, Daniel G. , Borges, Virginia F. , Warner, Ellen , Neuberg, Donna , Ebert, Benjamin L. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: e24108-e24108

10.1200/jco.2021.39.15_suppl.e24108 Get It

e24108 Background: Clonal hematopoiesis of Indeterminate Potential (CHIP) is associated with adverse clinical outcomes including increased risk of hematologic malignancies and heart disease. Limited data suggest an increased prevalence of CHIP in patients treated for solid tumors, particularly after exposure to radiation and chemotherapy. CHIP testing may inform risk-reduction strategies for cancer survivors. Little is known about patient knowledge, attitudes, and preferences regarding CHIP testing. Methods: We surveyed survivors without history of recurrence participating in an ongoing prospective cohort study of young women with breast cancer (BC). The survey was sent by email and included an introduction to CHIP including risk factors and clinical associations. Respondents then reviewed a vignette and were asked about CHIP testing preferences (definitely/probably test vs. definitely/probably not test) considering sequentially: 1) population-based 10-year risk of BC recurrence, hematological malignancy and heart disease; 2) estimated increase in these risks with CHIP; 3) current CHIP management; 4) a dedicated CHIP clinic; and 5) a theoretical CHIP treatment. Changes in preferences from the prior scenario were evaluated with the McNemar's test using a type I error rate of 5%. Results: 528/642 (82.2%) eligible women responded to the survey, at a median age of 46 (range: 31-54) years (median time from diagnosis: 108 months (range: 60-168)), and 88% were white. Most had stage 1/2 BC (78.8%) and had received chemotherapy (73.1%) and/or radiation (61.9%). 93.6% had never heard of CHIP prior to survey. After initial patient vignette presentation, most women (87.1%,) recommended CHIP testing if offered. Preferences for testing decreased (p<0.05) when considering population-based risks, with 11.1% shifting their preference from CHIP testing to not testing. After considering increased risks associated with CHIP, interest in testing increased (p<0.05), with 10.1% shifting their preference to testing. Interest significantly (p<0.05) increased with the possibility of managing CHIP through a clinic or a hypothetical CHIP treatment, with 7.2% and 14.1% switching their preferences towards testing, respectively. Finally, 75.8% responded that they themselves, after learning about CHIP and reviewing the vignette, would want to have CHIP testing; 28.2% reported that learning about CHIP and the associated risks caused them at least moderate anxiety. Conclusion: Few young BC survivors were aware of CHIP yet most indicated an interest in testing after learning about it. Testing preferences were influenced by risks presented and potential management strategies. Findings highlight the importance of effective risk communication and the need for adequate psychosocial support when considering testing for CHIP and other potential clinical biomarkers predictive of cancer and other medical risks in cancer survivors.
Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities
Mehta, Dev , Garza, Ivan , Robertson, Carrie E. , Mehta, Dev G , Robertson, Carrie E

Mayo Clinic

Cephalalgia | February 22, 2021 | Volume: 41 | Issue: 9 | Pages: 1015-1026

10.1177/0333102421996355 | PMID 33615842 Get It

Objective To review characteristics and outcomes of all cases of visual snow seen at our institution, with attention to possible triggering events or comorbidities. Methods This is a retrospective case series of patients seen at our tertiary care center from January 1994 to January 2020. Charts were reviewed if they contained the term “visual snow”. Results Of the 449 charts reviewed, 248 patients described seeing visual snow in part or all of their vision. Thirty-eight reported transient visual snow as their typical migraine aura. Of the remaining 210 patients, 89 were reported to have either an inciting event or contributing comorbidity for their visual snow symptoms, including: Post-concussion (n = 15), dramatic change in migraine or aura (n = 14), post-infection (n = 13), hallucinogen persisting perception disorder (n = 10), ocular abnormalities (n = 7), idiopathic intracranial hypertension (n = 4), neoplastic (n = 1), and posterior cortical atrophy (n = 1). Some patients had partial improvement with benzodiazepines (n = 6), lamotrigine (n = 5), topiramate (n = 3) and acetazolamide (n = 3). Presenting characteristics were similar, but patients with visual snow attributed to an inciting event or contributing comorbidity were more likely to have some improvement in their symptoms by last follow-up compared to spontaneous visual snow ( p < .001). Conclusions Though most cases of visual snow are spontaneous, potential secondary causes should be recognized by clinicians. Patients who develop visual snow after an inciting event or related to an underlying comorbidity may have a better prognosis than those in whom it develops spontaneously. In select cases, treatment of the suspected underlying cause may significantly alleviate the otherwise typical intractable visual disturbances associated with visual snow.
Bioelectronic Sensor Technology for Detection of Cystic Fibrosis and Hereditary Hemochromatosis Mutations
Bernacki, Susan H. , Farkas, Daniel H., Shi, Wenmei, Chan, Vivian, Liu, Yenbou, Beck, Jeanne C., Bailey, Karen Snow, Pratt, Victoria M. , Monaghan, Kristin G. , Matteson, Karla J., Schaefer, Frederick V., Friez, Michael J., Shrimpton, Antony E., Stenzel, Timothy T. , Chan, Vivian

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 8, 2021 | Volume: 127 | Issue: 12 | Pages: 1565-1572

10.5858/2003-127-1565-bstfdo | PMID 14632577 Get It

Abstract Context. —Bioelectronic sensors, which combine microchip and biological components, are an emerging technology in clinical diagnostic testing. An electronic detection platform using DNA biochip technology (eSensor) is under development for molecular diagnostic applications. Owing to the novelty of these devices, demonstrations of their successful use in practical diagnostic applications are limited. Objective. —To assess the performance of the eSensor bioelectronic method in the validation of 6 Epstein-Barr virus–transformed blood lymphocyte cell lines with clinically important mutations for use as sources of genetic material for positive controls in clinical molecular genetic testing. Two cell lines carry mutations in the CFTR gene (cystic fibrosis), and 4 carry mutations in the HFE gene (hereditary hemochromatosis). Design. —Samples from each cell line were sent for genotype determination to 6 different molecular genetic testing facilities, including the laboratory developing the DNA biochips. In addition to the bioelectronic method, at least 3 different molecular diagnostic methods were used in the analysis of each cell line. Detailed data were collected from the DNA biochip output, and the genetic results were compared with those obtained using the more established methods. Results. —We report the successful use of 2 applications of the bioelectronic platform, one for detection of CFTR mutations and the other for detection of HFE mutations. In all cases, the results obtained with the DNA biochip were in concordance with those reported for the other methods. Electronic signal output from the DNA biochips clearly differentiated between mutated and wild-type alleles. This is the first report of the use of the cystic fibrosis detection platform. Conclusions. —Bioelectronic sensors for the detection of disease-causing mutations performed well when used in a “real-life” situation, in this case, a validation study of positive control blood lymphocyte cell lines with mutations of public health importance. This study illustrates the practical potential of emerging bioelectronic DNA detection technologies for use in current molecular diagnostic applications.
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin
Navari, Rudolph M. , Ruddy, Kathryn J. , LeBlanc, Thomas W. , Clark-Snow, Rebecca, Binder, G. , Bailey, William L., Schmerold, Luke, Papademetriou, Eros , Roeland, Eric , Schmerold, Luke M , Leblanc, Thomas , Roeland, Eric J , Nipp, Ryan David , Schwartzberg, Lee Steven , Potluri, Ravi C.

Mayo Clinic

The Oncologist | December 2, 2020 | Volume: 26 | Issue: 4 | Pages: 325-331

10.1002/onco.13620 | PMID 33289268 Get It

Abstract Purpose Chemotherapy-induced nausea and vomiting (CINV) contributes to avoidable acute care, a metric now tracked in Medicare's oncology outcome measure. CINV is preventable, yet guidelines are often not followed. We sought to quantify acute care involving CINV and other avoidable toxicities after highly emetogenic chemotherapy (HEC) to identify excess risk and assess clinician adherence to antiemesis guidelines for HEC. Materials and Methods We retrospectively evaluated U.S. electronic health records (2012-2018) using Medicare's OP-35 outcome measure to identify avoidable acute care involving any of 10 toxicities, including CINV, after HEC regimens relative to non-HEC. Antiemetic guideline adherence was defined as use ofneurokinin-1 (NKl) receptor antagonists Q5 (RAs) plus 5-hydroxytryptamine type 3 RA+ dexamethasone at HEC initiation. Results Among 17,609 patients receiving HEC, acute care rates associated with HEC chemotherapy included 32% cisplatin, 31% carboplatin, and 21% anthracycline/cyclosphospharnide (AC), with 76% meeting the criteria as avoidable events. Oxaliplatin rates were 29%. Avoidable acute care occurred 1.83 times (95% confidence interval, 1.76-1.91, p &lt; .0001) as often after HEC versus non-HEC excluding oxaliplatin; CINV-related acute care occurred 2.29 times as often. Nonadherence to antiemesis guidelines occurred in 34% and 24% of cisplatin and AC courses, respectively, because of omission of a NKl RA. Conclusions Patients treated with HEC regimens experienced high avoidable acute care use, 1.8 times the risk seen for other chemotherapy. Nonadherence to guideline-directed antiemetic prophylaxis highlights the need to ensure adherence to antiemetic guidelines, including the use of NKl RA in HEC. Implications for Practice After survival, perhaps the most important goal in oncology is limiting avoidable acute care, a goal now used by Medicare to impact cancer reimbursement. This study found that patients treated with highly emetogenic chemotherapy (HEC) regimens had high rates of avoidable acute care use, 1.8 times the risk seen for other chemotherapy. A substantial proportion of the avoidable acute care involved chemotherapy-induced nausea and vomiting. Results showed that incomplete adherence to national antiemetic guidelines for HEC regimens primarily driven by omission of upfront neurokinin-1 receptor antagonist use, suggesting that improved adherence can meaningfully resolve this gap in quality and cost of care.
[ 123 I]-IMP single-photon emission computed tomography imaging in visual snow syndrome: A case series
Shibata, Mamoru , Tsutsumi, Kei, Iwabuchi, Yu , Kameyama, Masashi , Nakahara, Tadaki , Fujiwara, Hirokazu , Jinzaki, Masahiro , Takizawa, Tsubasa , Nakahara, Jin , Dodick, David W.

Mayo Clinic

Cephalalgia | August 14, 2020 | Volume: 40 | Issue: 14 | Pages: 1671-1675

10.1177/0333102420950454 | PMID 32791921 Get It

Background Visual snow syndrome (VSS) is a neurological condition characterized by persistent flickering dots in the visual fields, palinopsia, enhanced entoptic phenomenon, photophobia, and nyctalopia. Neuroimaging evidence supports the role of the visual association cortex in visual snow syndrome. Case series: We provided clinical care to three patients with visual snow syndrome, in whom [ 123 I]-IMP single-photon emission computed tomography (SPECT) imaging was performed. Case 1 was a 21-year-old male with a past history of migraine with aura who exhibited visual snow and entoptic phenomenon. In this patient, [ 123 I]-IMP SPECT imaging revealed right occipital and temporal hypoperfusion with a distribution matching the ventral visual stream. [ 123 I]-IMP SPECT imaging detected only mild bilateral frontal hypoperfusion in Case 2 and no overt abnormalities in Case 3. Conclusion Although visual snow syndrome seems to be a heterogenous condition, our observations indicate that abnormal visual processing within the ventral visual stream may play a role in the pathogenesis of this condition.
Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Navari, Rudolph M. , Ruddy, Kathryn J. , Clark-Snow, Rebecca, Wickham, Rita S., Binder, G. , Bailey, William L., Turini, Marco, Schmerold, Luke, Schwartzberg, Lee Steven , LeBlanc, Thomas W. , Potluri, Ravi C. , Roeland, Eric

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e24133-e24133

10.1200/jco.2020.38.15_suppl.e24133 Get It

e24133 Background: The impact of chemotherapy-induced nausea and vomiting (CINV) on work loss and activity impairment is important to patients yet not well described in literature. We sought to evaluate CINV-related work loss and activity impairment and their associations with CINV duration. Methods: In a prospective CINV prophylaxis trial of oral or intravenous netupitant/palonestron (NEPA) + dexamethasone (DEX) (12mg day 1 only) for patients with breast cancer receiving anthracycline + cyclophosphamide (AC), we defined CINV as vomiting or use of rescue medication during days 1-5 after AC. Pre-specified endpoints included CINV duration (0-5 days), patient reported CINV-associated work loss (Work Productivity and Activity Impairment survey), and CINV-related impaired activity [0 (none) - (worst) Likert scale] for chemotherapy cycles 1 and 2. CINV-related work loss and activity impairment could involve nausea with or without vomiting or rescue medication use. We categorized CINV duration as 1-2 days (d) or ≥3 d, and compared results using the chi-squared test. We report here on the first 2 cycles. Results: Survey data was captured for 792 cycles in 402 female patients including 132 (32.8%) employed patients. Mean age was 55.4. CINV was observed in 173 (21.8%) of total cycles. CINV-related work loss was reported in 26 (3.3% of all cycles, 15.0% of cycles with CINV, 38.2% of employed patient cycles with CINV) while 142 had related activity impairment. When we categorized cycles by CINV duration, CINV-related work loss was seen in 25.9% of 81 cycles with ≥3 d CINV duration vs. 5.4% for 92 cycles of 1-2 d of CINV (p < 0.001); mean scores of CINV-related impaired activity were 5.0 for ≥3 d CINV vs 3.0 for 1-2 d CINV (p < 0.001). Conclusions: Despite guideline recommended prophylaxis, CINV occurred in > 20% of AC cycles. In cycles with CINV, CINV-related work loss occurred in 38.2% for employed patients while activity impairment occurred in 82.1% for all patient cycles. The majority of CINV lasted 1-2 d. Notably, ≥3 d of CINV was associated with considerably higher levels of work loss and activity impairment suggesting that duration may be a meaningful measure of CINV impact. Clinical trial information: NCT03403712 . [Table: see text]
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.
Sella, Tal , Gelber, Shari , Poorvu, Philip D. , Kim, Hee Jeong , Arocho, Yaileen D Guzman, Collins, Laura C. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Russell, Christy , Rosenberg, Shoshana M. , Tamimi, Rulla M. , Borges, Virginia F. , Warner, Ellen , Snow, Craig , Jakubowski, Debbie , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 514-514

10.1200/jco.2020.38.15_suppl.514 Get It

514 Background: The 21- gene Breast Recurrence Score predicts benefit from adjuvant chemotherapy in estrogen receptor positive (ER+), HER-2 negative (-) breast cancer (BC). We aimed to examine whether the 21-gene assay predicts response to neoadjuvant chemotherapy (NAC). Methods: We identified patients with stage I-III ER+/HER2− BC treated with NAC from the Young Women's Breast Cancer Study, a prospective cohort of women diagnosed with BC at age ≤ 40 years. The 21-gene assay was performed on tumor specimens removed prior to NAC either as part of clinical care or retrospectively for research. Pathologic complete response (pCR) was defined as no residual invasive tumor (ypT0/is ypN0). The relationship between Recurrence Score result (RS) and pCR was evaluated using logistic regression modeling. Results: 76 women in the cohort had undergone NAC for ER+, HER2- BC and were eligible for this analysis: 5 had undergone clinical 21-gene assay testing, 71 had banked specimens retrospectively tested. Median age at diagnosis was 36.7 (24.3-40). Most tumors were of ductal histology (78%), high grade (51%), progesterone receptor (PgR) positive (86%), ≥T2 (88%), clinically node positive (74%), and anthracycline and taxane containing protocols were administered in 86% of cases. RS ranged between 5-75 with 50% > 25 and only 4 < 11. Mean RS was significantly higher among tumors achieving pCR vs. non-pCR response (51.9 vs. 26.6, pwilcoxon= 0.0005). pCR rate in patients with RS > 25 was 21% (8/38) vs. 5% in patients with RS < 25 (2/38), with both pCRs in the <25 group in patients with RS 21-25. In univariable analysis, PgR negativity (odds ratio (OR) 5.62, 95% confidence interval (CI) 1.27-24.89, p = 0.02), high grade (OR 9.03, 95%CI 1.07-76.32, p = 0.04) and higher RS as a continuous variable (OR 1.08, 95%CI 1.04-1.13, p = 0.0003) were associated with a greater likelihood of pCR. In multivariable analysis only RS remained significantly associated with pCR (OR: 1.07, 95%CI 1.01-1.12, p = 0.01): a 7% increase in the odds of pCR for every 1-point increase in RS. Conclusions: In young women with ER+, HER2- BC who received NAC, higher pretreatment RS was associated with an increased likelihood of pCR. Genomic expression profiling assays may have a role in decision-making in young women in need of neoadjuvant therapy. For women with low likelihood of benefiting from NAC, alternative approaches are clearly warranted. Given the demonstrated efficacy of neoadjuvant endocrine therapy in post-menopausal women, further evaluation in young women should be pursued.